Literature DB >> 9487350

Cryptogenic fibrosing alveolitis with preserved lung volumes.

M J Doherty1, M G Pearson, E A O'Grady, V Pellegrini, P M Calverley.   

Abstract

BACKGROUND: Cryptogenic fibrosing alveolitis (CFA) is an uncommon disorder of unknown aetiology characterised by interstitial fibrosis which typically shows a restrictive pattern on pulmonary function testing. Some patients with CFA and relative preservation of lung volumes have been described and it has been suggested that their volume preservation may be due to concomitant emphysema. In a retrospective study the relative frequency of preserved lung volumes in CFA, its relationship to emphysema determined by CT scanning, its clinical features, and its subsequent natural history were investigated.
METHODS: Using predefined characteristics 48 patients with CFA were identified from pulmonary function records over a three year period. Volume preservation was defined as a forced vital capacity (FVC) of > 80% predicted at presentation. Patients with relative volume preservation were compared with those with more typical pulmonary restriction and clinical data at presentation, and details of their subsequent prognosis, treatment and loss of lung function with time were obtained. Where available, computed tomographic (CT) scans for the two groups were compared in a blinded fashion to score the extent of fibrosis and the presence of concomitant emphysema.
RESULTS: Twenty one (44%) of the patients with CFA had a FVC of > 80% predicted. They were more likely to be male (76% versus 48%) and to be current smokers (57% versus 22%) with a heavier life time cigarette consumption than the restricted patients (mean (SE) 38 (4.6) versus 25 (4.5) pack years). There were no significant differences in prognosis and subsequent treatment between the groups. Comparable HRCT scans were available in 23 subjects (seven preserved, 16 restricted). They showed no difference in extent of the pulmonary fibrosis but patients with volume preservation were more likely to show concomitant emphysema (86% versus 19%). Patients with emphysema on HRCT scans were heavier smokers (41(10) versus 21(17) pack years) than those without emphysema but there was no difference in the extent of CFA score between the two groups.
CONCLUSIONS: In this area of high smoking prevalence a significant number of patients with CFA presented with relative preservation of lung volumes and FEV1/FVC ratio. In many of these subjects this appears to reflect coincidental emphysema. This may make interpretation of gas transfer factor used to monitor progression in CFA difficult. However, there was no evidence that lung volumes at presentation were of prognostic significance.

Entities:  

Mesh:

Year:  1997        PMID: 9487350      PMCID: PMC1758455          DOI: 10.1136/thx.52.11.998

Source DB:  PubMed          Journal:  Thorax        ISSN: 0040-6376            Impact factor:   9.139


  10 in total

1.  Sensitivity of the cough reflex in patients with chronic cough.

Authors:  N B Choudry; R W Fuller
Journal:  Eur Respir J       Date:  1992-03       Impact factor: 16.671

2.  Clinical and physiologic features of some types of pulmonary diseases with impairment of alveolar-capillary diffusion; the syndrome of "alveolar-capillary block".

Authors:  R AUSTRIAN; J H McCLEMENT; A D RENZETTI; K W DONALD; R L RILEY; A COURNAND
Journal:  Am J Med       Date:  1951-12       Impact factor: 4.965

3.  Correlation of structure and function in idiopathic pulmonary fibrosis.

Authors:  R M Cherniack; T V Colby; A Flint; W M Thurlbeck; J A Waldron; L Ackerson; M I Schwarz; T E King
Journal:  Am J Respir Crit Care Med       Date:  1995-04       Impact factor: 21.405

4.  Lone cryptogenic fibrosing alveolitis: a functional-morphologic correlation based on extent of disease on thin-section computed tomography.

Authors:  A U Wells; A D King; M B Rubens; D Cramer; R M du Bois; D M Hansell
Journal:  Am J Respir Crit Care Med       Date:  1997-04       Impact factor: 21.405

5.  Observer variation in pattern type and extent of disease in fibrosing alveolitis on thin section computed tomography and chest radiography.

Authors:  C D Collins; A U Wells; D M Hansell; R A Morgan; J E MacSweeney; R M du Bois; M B Rubens
Journal:  Clin Radiol       Date:  1994-04       Impact factor: 2.350

6.  The epidemiology of interstitial lung diseases.

Authors:  D B Coultas; R E Zumwalt; W C Black; R E Sobonya
Journal:  Am J Respir Crit Care Med       Date:  1994-10       Impact factor: 21.405

7.  Cryptogenic fibrosing alveolitis: clinical features and their influence on survival.

Authors:  M Turner-Warwick; B Burrows; A Johnson
Journal:  Thorax       Date:  1980-03       Impact factor: 9.139

8.  Determinants of progression in idiopathic pulmonary fibrosis.

Authors:  D A Schwartz; D S Van Fossen; C S Davis; R A Helmers; C S Dayton; L F Burmeister; G W Hunninghake
Journal:  Am J Respir Crit Care Med       Date:  1994-02       Impact factor: 21.405

Review 9.  Idiopathic pulmonary fibrosis. Clinical, histologic, radiographic, physiologic, scintigraphic, cytologic, and biochemical aspects.

Authors:  R G Crystal; J D Fulmer; W C Roberts; M L Moss; B R Line; H Y Reynolds
Journal:  Ann Intern Med       Date:  1976-12       Impact factor: 25.391

10.  The predictive value of appearances on thin-section computed tomography in fibrosing alveolitis.

Authors:  A U Wells; D M Hansell; M B Rubens; P Cullinan; C M Black; R M du Bois
Journal:  Am Rev Respir Dis       Date:  1993-10
  10 in total
  20 in total

Review 1.  Clinical usefulness of high resolution computed tomography in cryptogenic fibrosing alveolitis.

Authors:  A Wells
Journal:  Thorax       Date:  1998-12       Impact factor: 9.139

Review 2.  Idiopathic pulmonary fibrosis: pathogenesis and therapeutic approaches.

Authors:  Moisés Selman; Victor J Thannickal; Annie Pardo; David A Zisman; Fernando J Martinez; Joseph P Lynch
Journal:  Drugs       Date:  2004       Impact factor: 9.546

3.  Smoking-related idiopathic interstitial pneumonia.

Authors:  Kevin R Flaherty; Charlene Fell; Marie-Christine Aubry; Kevin Brown; Thomas Colby; Ulrich Costabel; Teri J Franks; Barry H Gross; David M Hansell; Ella Kazerooni; Dong Soon Kim; Talmadge E King; Masanori Kitachi; David Lynch; Jeff Myers; Sonoko Nagai; Andrew G Nicholson; Venerino Poletti; Ganesh Raghu; Moises Selman; Galen Toews; William Travis; Athol U Wells; Robert Vassallo; Fernando J Martinez
Journal:  Eur Respir J       Date:  2014-07-25       Impact factor: 16.671

4.  Surgical Outcomes of Lung Cancer Patients with Combined Pulmonary Fibrosis and Emphysema and Those with Idiopathic Pulmonary Fibrosis without Emphysema.

Authors:  Seijiro Sato; Terumoto Koike; Takehisa Hashimoto; Hiroyuki Ishikawa; Akira Okada; Takehiro Watanabe; Masanori Tsuchida
Journal:  Ann Thorac Cardiovasc Surg       Date:  2016-04-05       Impact factor: 1.520

Review 5.  Pulmonary function testing in idiopathic interstitial pneumonias.

Authors:  Fernando J Martinez; Kevin Flaherty
Journal:  Proc Am Thorac Soc       Date:  2006-06

Review 6.  Combined pulmonary fibrosis and emphysema syndrome: a review.

Authors:  Matthew D Jankowich; Sharon I S Rounds
Journal:  Chest       Date:  2012-01       Impact factor: 9.410

7.  Fibrosing alveolitis in patients with rheumatoid arthritis as assessed by high resolution computed tomography, chest radiography, and pulmonary function tests.

Authors:  J K Dawson; H E Fewins; J Desmond; M P Lynch; D R Graham
Journal:  Thorax       Date:  2001-08       Impact factor: 9.139

8.  Combined pulmonary fibrosis and emphysema alters physiology but has similar mortality to pulmonary fibrosis without emphysema.

Authors:  Matthew D Jankowich; Sharon Rounds
Journal:  Lung       Date:  2010-07-08       Impact factor: 2.584

Review 9.  Pathogenetic mechanisms in usual interstitial pneumonia/idiopathic pulmonary fibrosis.

Authors:  Eric S White; Michael H Lazar; Victor J Thannickal
Journal:  J Pathol       Date:  2003-11       Impact factor: 7.996

10.  Traction bronchiectasis in cryptogenic fibrosing alveolitis: associated computed tomographic features and physiological significance.

Authors:  Sujal R Desai; Athol U Wells; Michael B Rubens; Roland M du Bois; David M Hansell
Journal:  Eur Radiol       Date:  2002-12-19       Impact factor: 5.315

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.